Sander Slootweg, Forbion
Driven by Covid-19 fever, Forbion notes investor interest in vaccines and new therapies as part of $557M fund
Nearly a year into the Covid-19 pandemic, a wave of investment in novel therapies and vaccines to fight the virus has continued to flow—and investors …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
